Literature DB >> 29060958

A Case of Hypertensive Crisis without a Surge in Adrenal Hormones after Radiofrequency Ablation as a Treatment for Primary Hepatocellular Carcinoma.

Kyung Jin Lee1, Soo Hyung Ryu1.   

Abstract

Radiofrequency ablation (RFA) is a minimally invasive procedure that has been considered as a relatively safe treatment for patients with small hepatocellular carcinoma (HCC). However, RFA has been shown to be associated with complications including mechanical and thermal damage. A 74-year-old man with hepatitis C virus-associated HCC was admitted to our hospital. Abdominal computed tomography revealed two lobulated-HCC in segments 4 and 5. He had no medical history of hypertension and cardiac disease. During RFA, blood pressure was elevated to 200/140 mmHg. There was no evidence of pulmonary embolism, aortic dissection, or ischemic heart disease. Laboratory findings for catecholamine surge were all within normal limits. After continuous intravenous nitroglycerin and oral beta-blocker treatment, patient's blood pressure gradually decreased and back within the normal range. Hypertensive crisis after RFA treatment for HCC is rare. Most reported cases of hypertensive crisis during RFA were related to adrenal gland injury with a release of catecholamine. In our case, the site of HCC was not close to the adrenal gland, and there was no evidence of catecholamine surge. Herein, we report a very rare case of hypertensive crisis without a surge in adrenal hormones after RFA treatment for HCC.

Entities:  

Keywords:  Carcinoma, hepatocellular; Hypertension; Hypertensive crisis; Radiofrequency catheter ablation

Mesh:

Substances:

Year:  2017        PMID: 29060958     DOI: 10.4166/kjg.2017.70.4.198

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  1 in total

1.  Risk factor for vital signs elevation during percutaneous microwave ablation of liver tumor under deep sedation.

Authors:  Wen-Tao Wu; Wei-Zhong Zhou; Qing-Quan Zu; Zhen-Yu Jia; Bin Leng; Sheng Liu; Hai-Bin Shi; Yu Chen
Journal:  Jpn J Radiol       Date:  2021-06-26       Impact factor: 2.374

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.